Marco Chiumente

14PUBLICATIONS
18CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesModelling and simulationMolecular targetsDisease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|May 25, 2024
Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort ("PEMBROREAL" Study).

Alessandro Cafaro, Flavia Foca, Oriana Nanni

|Dec 22, 2023
Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons.

Melania Rivano, Daniele Mengato, Marco Chiumente

|Apr 13, 2023
Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens.

Andrea Ossato, Daniele Mengato, Marco Chiumente

|Mar 29, 2023
Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses.

Andrea Messori, Vera Damuzzo, Melania Rivano

|Sep 09, 2022
Survival with novel hormonal therapies in patients with nonmetastatic castration-resistant prostate cancer: indirect comparison of three randomized phase-III trials.

Melania Rivano, Luca Cancanelli, Lorenzo Di Spazio

|Aug 03, 2022
Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data.

Andrea Ossato, Vera Damuzzo, Paolo Baldo

Pageof 3

Frequent Collaborators

10 joint publications

Daniele Mengato

8 joint publications

Melania Rivano

8 joint publications

Andrea Messori

7 joint publications

Luca Cancanelli